Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Coppo

Showing results (161-170 of 199) with videos related to

Pageof 20
Sort By:
Blood|August 19, 2020
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working groupFadi Fakhouri, Marie Scully, François Provôt, et al.
Haematologica|November 25, 2017
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic AnemiaEtienne Lengline, Bernard Drenou, Pierre Peterlin, et al.
Blood|December 14, 2006
Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activitySilvia Ferrari, Friedrich Scheiflinger, Manfred Rieger, et al.
Intensive Care Medicine|October 8, 2019
Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpuraElie Azoulay, Philippe R Bauer, Eric Mariotte, et al.
European Journal of Haematology|April 16, 2019
Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphomaEtienne Crickx, Elsa Poullot, Guillaume Moulis, et al.
Blood|February 2, 2021
Redefining outcomes in immune TTP: an international working group consensus reportAdam Cuker, Spero R Cataland, Paul Coppo, et al.
Critical Care Medicine|September 20, 2011
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference CenterAntoine Froissart, Marc Buffet, Agnès Veyradier, et al.
Intensive Care Medicine|January 23, 2020
Correction to: Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpuraElie Azoulay, Philippe R Bauer, Eric Mariotte, et al.
American Journal of Hematology|January 31, 2017
Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centreMaximilien Grall, Elie Azoulay, Lionel Galicier, et al.
AIDS (London, England)|September 20, 2017
Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy eraCaroline Besson, Remi Lancar, Sophie Prevot, et al.
Pageof 20

Showing results (161-170 of 199) with videos related to

Sort By:
Pageof 20
Blood|August 19, 2020
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working groupFadi Fakhouri, Marie Scully, François Provôt, et al.
Haematologica|November 25, 2017
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic AnemiaEtienne Lengline, Bernard Drenou, Pierre Peterlin, et al.
Blood|December 14, 2006
Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activitySilvia Ferrari, Friedrich Scheiflinger, Manfred Rieger, et al.
Intensive Care Medicine|October 8, 2019
Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpuraElie Azoulay, Philippe R Bauer, Eric Mariotte, et al.
European Journal of Haematology|April 16, 2019
Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphomaEtienne Crickx, Elsa Poullot, Guillaume Moulis, et al.
Blood|February 2, 2021
Redefining outcomes in immune TTP: an international working group consensus reportAdam Cuker, Spero R Cataland, Paul Coppo, et al.
Critical Care Medicine|September 20, 2011
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference CenterAntoine Froissart, Marc Buffet, Agnès Veyradier, et al.
Intensive Care Medicine|January 23, 2020
Correction to: Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpuraElie Azoulay, Philippe R Bauer, Eric Mariotte, et al.
American Journal of Hematology|January 31, 2017
Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centreMaximilien Grall, Elie Azoulay, Lionel Galicier, et al.
AIDS (London, England)|September 20, 2017
Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy eraCaroline Besson, Remi Lancar, Sophie Prevot, et al.
Pageof 20